Cargando…

A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes

Most antibody–drug conjugates (ADC) approved for the treatment of cancer contain protease-cleavable linkers. ADCs that traffic to lysosomes traverse highly acidic late endosomes, while ADCs that recycle to the plasma membrane traffic through mildly acidic sorting and recycling endosomes. Although en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez Bay, Andres E., Faulkner, Devon, DaSilva, John O., Young, Tara M., Yang, Katie, Giurleo, Jason T., Ma, Dangshe, Delfino, Frank J., Olson, William C., Thurston, Gavin, Daly, Christopher, Andreev, Julian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Large Molecule Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978886/ https://www.ncbi.nlm.nih.gov/pubmed/36861363 http://dx.doi.org/10.1158/1535-7163.MCT-22-0414

Ejemplares similares

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
por: DaSilva, John O., et al.
Publicado: (2021)

Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
por: Wang, Peiyin, et al.
Publicado: (2022)

IMiDs Augment CD3-Bispecific Antibody–Induced CD8(+) T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production
por: Li, Ji, et al.
Publicado: (2023)

The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
por: Nelson, Michelle H., et al.
Publicado: (2023)

Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
por: Groothuis, Patrick G., et al.
Publicado: (2023)

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
por: Grinkevitch, Vera, et al.
Publicado: (2022)

Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
por: Buongervino, Samantha, et al.
Publicado: (2021)

A FZD7-specific Antibody–Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models
por: Do, Myan, et al.
Publicado: (2022)

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
por: Pegram, Mark D., et al.
Publicado: (2021)

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy
por: Puttemans, Janik, et al.
Publicado: (2022)

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo
por: Montes de Oca, Rocio, et al.
Publicado: (2021)

Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
por: Klempner, Samuel J., et al.
Publicado: (2021)

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway
por: Wurm, Melanie, et al.
Publicado: (2021)

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
por: Harper, James, et al.
Publicado: (2021)

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
por: Gordon, Michael S., et al.
Publicado: (2021)

Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
por: Wang, Beatrice T., et al.
Publicado: (2021)

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
por: Hooper, Andrea T., et al.
Publicado: (2022)

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
por: Tomar, Sakshi, et al.
Publicado: (2022)

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
por: Zammarchi, Francesca, et al.
Publicado: (2022)

Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
por: Hollmén, Maija, et al.
Publicado: (2022)

DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
por: Yamato, Michiko, et al.
Publicado: (2022)

Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
por: Buonato, Janine M., et al.
Publicado: (2022)

ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
por: Wiedemeyer, Wolf R., et al.
Publicado: (2022)

Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy
por: Iwai, Toshiki, et al.
Publicado: (2021)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
por: Kopp, Anna, et al.
Publicado: (2023)

Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
por: Singh, Shweta, et al.
Publicado: (2022)

A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer
por: Chen, Mao-Lin, et al.
Publicado: (2022)

Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
por: Evans, Rachel J., et al.
Publicado: (2023)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins
por: Aasted, Mikkel K.M., et al.
Publicado: (2023)

Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2023)

S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
por: Nagira, Yoji, et al.
Publicado: (2023)

A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies
por: Zitzmann-Kolbe, Sabine, et al.
Publicado: (2023)

Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFR(pos) Mouse Xenograft Model
por: Huet, Simon, et al.
Publicado: (2023)

FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment
por: Shimoyama, Susumu, et al.
Publicado: (2023)

SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
por: Lyon, Robert P., et al.
Publicado: (2023)

Sulfatase-cleavable linkers for antibody-drug conjugates
por: Bargh, Jonathan D., et al.
Publicado: (2020)

Peroxide-cleavable linkers for antibody–drug conjugates
por: Ashman, Nicola, et al.
Publicado: (2023)

Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates
por: Balamkundu, Seetharamsing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_refd87776qbc9i6h8fsd949ig4